HCG
Also known as Human Chorionic Gonadotropin
Last reviewed September 26, 2026
HCG is a glycoprotein hormone studied for its activity at the luteinizing hormone receptor, and for its role in research on the hypothalamic-pituitary-gonadal axis.
Mechanism of action
Research describes HCG as structurally similar enough to luteinizing hormone to act at the same receptor, studied for downstream endogenous hormone production.
- LH ReceptorStudied for activity at the luteinizing hormone receptor due to close structural similarity.
- Endocrine AxisExplored in research on maintaining endogenous production within the reproductive hormone axis.
- Route studied
- Subcutaneous
- Research status
- Approved analog
HCG is an established clinical hormone, with reviews and meta-analyses describing its use in the management of secondary hypogonadism, male infertility and pubertal induction in hypogonadotropic hypogonadism.
What the research covers
What research examines
- Luteinizing hormone receptor activity
- Endogenous hormone production within the hypothalamic-pituitary-gonadal axis
- Management of secondary hypogonadism and male infertility
- Pubertal induction in males with hypogonadotropic hypogonadism
- Recovery from anabolic steroid-induced hypogonadism
- Non-testosterone approaches to male hypogonadism
Reported effects in studies
- Safety of HCG monotherapy has been examined in men with previous exogenous testosterone use
- Specific adverse event rates are not summarized in the cited study titles
- Acts on the reproductive hormone axis, so hormonal effects are a central consideration in research design
What research protocols have used
Research protocols have used around 500 IU per administration, 3 times per week, in 8-week blocks with 4 weeks off.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Every CoreX order ships with a per-lot protocol guide.
Open the reconstitution calculatorResearched alongside
Cited research
- Human chorionic gonadotropin treatment: a viable option for management of secondary hypogonadism and male infertility.
Expert review of endocrinology & metabolism · 2021 · Review · PubMed 33345656
- The Safety of Human Chorionic Gonadotropin Monotherapy Among Men With Previous Exogenous Testosterone Use.
Cureus · 2022 · PubMed 35822152
- Gonadotropins for pubertal induction in males with hypogonadotropic hypogonadism: systematic review and meta-analysis.
European journal of endocrinology · 2024 · Meta-analysis · PubMed 38128110
- Non-testosterone management of male hypogonadism: an examination of the existing literature.
Translational andrology and urology · 2020 · Review · PubMed 32257856
- Anabolic steroid-induced hypogonadism: diagnosis and treatment.
Fertility and sterility · 2014 · Meta-analysis · PubMed 24636400
Questions about HCG
HCG, or human chorionic gonadotropin, is a glycoprotein hormone studied for its activity at the luteinizing hormone receptor. It is a frequent subject of research on the hypothalamic-pituitary-gonadal axis, the hormonal system that regulates reproductive hormone production. Published reviews discuss its role in secondary hypogonadism, male infertility and pubertal induction, making it one of the better-documented compounds in reproductive endocrinology research.
Research describes HCG as structurally similar enough to luteinizing hormone to act at the same receptor. Because of this similarity, it has been studied for its ability to stimulate downstream endogenous hormone production. Investigators have explored it in the context of maintaining production within the reproductive hormone axis, particularly in settings where the body's own luteinizing hormone signalling is reduced or suppressed.
Published literature has examined HCG in the management of secondary hypogonadism and male infertility, pubertal induction in males with hypogonadotropic hypogonadism, and recovery from anabolic steroid-induced hypogonadism. Reviews have also discussed it among non-testosterone approaches to male hypogonadism and in relation to preserving spermatogenesis alongside testosterone replacement. A systematic review and meta-analysis has assessed gonadotropins for pubertal induction.
One published study specifically examined the safety of HCG monotherapy among men with previous exogenous testosterone use. Detailed adverse event rates are not summarized in the cited study titles, so specific findings should be taken from the full publications. Because HCG acts directly on the reproductive hormone axis, hormonal effects are a central consideration in how research protocols are designed and monitored.
Research protocols have used around 500 IU per administration, 3 times per week, in 8-week blocks followed by 4 weeks off, with subcutaneous administration described. These figures reflect reported research protocols only and are not recommendations. Each CoreX order ships with a protocol guide for laboratory reference, and CoreX supplies HCG for laboratory research use only.
Ask about HCG
Our research assistant answers questions about the science, the studied ranges, and our products. It can be wrong, and it does not give medical advice.
HCG at CoreX
Every batch is independently tested for identity and purity, and the certificate of analysis is tied to the lot number on your label.
Longevity
$79.00









